Archive
553 articles, sorted by publication time.
UCI Health has launched a clinical trial of a neural stem cell therapy, opening a new path for Huntington’s disease, which has long lacked disease-modifying treatments; for now, however, its significance lies mainly in safety and feasibility, not a definitive conclusion on efficacy.
The 5,215 clinical drug trials make China’s R&D capacity harder to view as a peripheral phenomenon; the real test will be whether this volume can be converted into innovative drugs that are reproducible, reviewable, and bearable for patients.
The biotech stock story is shifting from single clinical readouts to a more complex investment narrative: whether artificial intelligence can improve R&D efficiency, and whether large pharmaceutical companies will use M&A to fill gaps in their pipelines. But ETF prices moving first does not mean new-drug risk has been rewritten.
An investment roundup included SOPHiA GENETICS in a discussion of AI drug discovery stocks, showing that the market is linking clinical genomic data, algorithmic platforms, and the prospect of new drug development; but from stock market themes to medical evidence, there remains a long road of validation and regulation.
A preprint model proposed by a Stanford team attempts to understand electrocardiograms, echocardiography, and cardiac MRI at the same time; it moves cardiac AI from single-image interpretation toward integrated decision-making, while also bringing issues of data bias, responsibility, and medical validation to the fore.
Zoldonrasib’s move from later-line exploration into a Phase 3 first-line trial in combination with chemotherapy represents the start of a more rigorous test, and one closer to real-world clinical practice, for RAS G12D pancreatic cancer treatment.
As the biosimilars market gradually matures, Celltrion emphasized AI drug discovery and antibody-drug conjugate capabilities at BIO USA, signaling not just a technology showcase but how a large biotech company is reorganizing R&D risk and its future pipeline.
Washington is trying to shorten the wait for early-stage human trials. Behind the effort is not only a question of regulatory efficiency, but also a stress test of the pressure to redistribute the U.S.-China biomedical R&D landscape.
This collaboration, worth up to about $2.75 billion, is not just about a large pharmaceutical company buying into the computing-power promise of an AI platform; it puts oral drug candidates, metabolic disease, and multi-indication development onto the same risk sheet, testing whether algorithm-generated products can truly be carried by clinical development and regulators.
Kalkine has put the spotlight on the AI drug-discovery narrative at Algorae Pharmaceuticals. For small biotech companies, what can truly translate into value is not “using AI,” but verifiable drug candidates, clear data sources, and the decision discipline needed to move into the clinic.
An arXiv preprint introduces BioResearcher: it does not merely answer questions, but connects literature, trials, patents, and multi-omics data into translational-medicine files with sources, disagreements, and rankings. Beyond its strong benchmark results, the real test is whether such systems can be trusted in clinical R&D workflows.
What appears to be an Indian pharmaceutical stock-market rally is in fact rooted in the fragility of the cancer treatment supply chain: when quality and capacity fall out of balance at the same time for inexpensive, mature, irreplaceable chemotherapy drugs, the pressure reaches the clinic before it reaches the capital market.